**Supplementary table S1. Results of the indirect and direct tests for HCV infection for the fourteen cases on biological samples available at the time of diagnosis and on previous visits**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Subject | Time | Indirect tests | Direct Tests | ALT | HCV genotype |
| EIA antibody (Architect) | Rapid tests | HCV RNA (UI/ml) | EIA Antigen(fmol/l) |
| Result | Index | TOYO | Oraquick | Cobas | Xpert | Result |
| HCV mono-infected |
| 1  | Md-2 |  |  |  |  | < 12 |  |  | 22 |  |
| Md-1 | Negative |  | Negative | Negative | 36000000 | NA | 50419 | 21 |  |
| Md*Jun-2014* | Positive | 11.24 | Positive | Positive | 1881837 | 47350 | 202 | 1822 | 1a |
|   |  |  |  |  |  |  |  |  |  |
| 2 | Md-2 |  |  |  |  | < 15 |  |  | 16 |  |
| Md-1 | Negative |  | NA | NA | 71063 | NA | NA | NA |  |
| Md*Sep-2012* | Positive | 8.91 | Positive | Positive | 9197466 | 8750000 | 16777 | 234 | 4d |
|   |  |  |  |  |  |  |  |  |  |
| 3 | Md-2 |  |  |  |  | < 15 |  |  | 20 |  |
| Md-1 | Negative |  | Negative | Negative | 175575 | 1860000 | 32654 | 33 |  |
| Md*Mar-2016* | Positive | 12.61 | Positive | Positive | 2416178 | 905000 | 2474 | 946 | 4d |
|  |  |  |  |  |  |  |  |  |  |
| 4 | Md-1 | Negative |  | Negative | Negative | 314 | D < 200 |  | 26 |  |
| Md*Nov-2015* | Positive | 5.05 | Negative | Positive | 4669004 | 2805000 | 13356 | 451 | 1a |
|  |  |  |  |  |  |  |  |  |  |
| 5 | Md-2 |  |  |  |  | < 15 |  |  | 18 |  |
| Md-1 | Negative |  | Negative | Negative | 34652715 | 9550000 | 34049 | 381 |  |
| Md*Oct-2015* | Positive | 8.56 | Positive | Positive | 5479 | 346000 | 938 | 3619 | 4d |
|  |  |  |  |  |  |  |  |  |  |
| 6 | Md-1 | Negative |  |  |  | < 15 | NA | NA | 14 |  |
| Md*May-2016* | Positive | 1.13 | Negative | Positive | 29301508 | 6300000 | 17311 | 95 | 3a |
|  |  |  |  |  |  |  |  |  |  |
| 7 | Md-1 | Negative |  |  |  | 1935372 | NA | NA | 22 |  |
| Md*Mar-2014* | Positive | 1.71 | Negative | Negative | 1197548 | 2900000 | NA | 65 | 1a |
|  |  |  |  |  |  |  |  |  |  |
| 8 | Md-2 |  |  |  |  | < 45 |  |  | 19 |  |
| Md-1 | Negative |  | Negative | Negative | 13338 | 6700 | 43 | 28 |  |
| Md*Sep-2014* | Positive | 9.85 | Positive | Positive | 10414 | 3785 | 12 | 92 | 1a |
|  |  |  |  |  |  |  |  |  |  |
| 9 | Md-1 | Negative |  | NA | NA | < 30 | NA | NA | 18 |  |
| Md*Nov-2014* | Positive | 9.34 | Positive | Positive | 207279 | 227500 | 776 | 470 | 4d |
|  |  |  |  |  |  |  |  |  |  |
| 10 | Md-2 |  |  |  |  | 195694 | NA |  | 30 |  |
| Md-1 | Negative |  | Negative | Negative | 289899 | 50250 | 261 | 83 |  |
| Md*Dec-2014* | Positive | 5.28 | Positive | Positive | 2391 | 2110 | 12 | 475 | 1a |
|  |  |  |  |  |  |  |  |  |  |
| 11 | Md-2 |  |  |  |  | <40 | <40 |  | 16 |  |
| Md-1 | Negative |  | Negative | Negative | 8630000 | 4215000 | 13754 | 37 |  |
| Md*Nov-2015* | Positive | 11.16 | Positive | Positive | 4466 | 1825 | 8 | 597 | 4d |
|  |  |  |  |  |  |  |  |  |  |
| 12 | Md-2 |  |  |  |  | NA | NA | NA | 41 |  |
| Md-1 | Negative |  | Negative | Negative | 6510000 | 1230000 | 5611 | 291 |  |
| Md*Nov-2012* | Positive | 12.38 | Positive | Positive | 3415663 | 902000 | 4505 | 265 | 4d |
|  |  |  |  |  |  |  |  |  |  |
| 13 | Md-2 |  |  |  |  | 7350000 | 4020000 | 9332 | 27 |  |
| Md-1 | Negative |  | Negative | Negative | 10900000 | 3210000 | 13196 | 82 |  |
| Md*Sep-2013* | Positive | 14.18 | Positive | Positive | 61242 | D < 200 | 2 | 103 | 4d |
| HCV-HIV co-infected |
| 14 | Md-2 |  |  |  |  | < 15 |  |  |  |  |
| Md-1 | Negative |  | NA | NA | NA | NA | NA | NA |  |
| Md*Mar-2014* | Positive | 13.55 | Positive | Positive | 2739867 | 8750000 | 5274 | NA | 1a |

Abbreviations: EIA, ELISA immune-assay; HCV, hepatitis C; NA, not available